Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 413 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Risk Breast Carcinoma Clear all
Completed Not applicable Interventional

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

NCT01097278
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

NCT04489940
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Newark, Delaware • Jacksonville, Florida • Silver Spring, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 27, 2026, 6:34 PM EDT
Not listed Phase 3 Interventional Results available

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

NCT00408408
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
1,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
432
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma

NCT00001270
View directory record Official record
Conditions
Breast Neoplasms, Lymphoma, Neoplasm Metastasis, Testicular Neoplasms
Interventions
interleukin-1
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

NCT04752332
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Abemaciclib, Standard Adjuvant ET, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Glendale, Arizona • Los Angeles, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 27, 2026, 6:34 PM EDT
Not listed Phase 2 Interventional

Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

NCT00280930
View directory record Official record
Conditions
Post-Menopausal, Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated No phase listed Observational

Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy

NCT00925405
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast MRI, Mammogram
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

NCT00918281
View directory record Official record
Conditions
Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
Interventions
Fluciclatide Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Not applicable Interventional

A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care

NCT02831439
View directory record Official record
Conditions
Breast Cancer
Interventions
Basic public reporting, Enhanced intervention, Control group - observational
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
400,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00003877
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
3
States / cities
Detroit, Michigan • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Interventions
letrozole, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Tucson, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 27, 2026, 6:34 PM EDT
Recruiting Phase 1 Interventional

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

NCT05996107
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Postoperative Radiation Therapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

NCT00052351
View directory record Official record
Conditions
Breast Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677
View directory record Official record
Conditions
HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1259
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 27, 2026, 6:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue

NCT03657628
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Intervention
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)/TRICOM vaccine, filgrastim, sargramostim, cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, Mesna
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812
View directory record Official record
Conditions
Breast Cancer, High Risk of Breast Cancer
Interventions
da Vinci SP Surgical System
Device
Lead sponsor
Deborah Farr, MD
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 27, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

NCT00625898
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
3,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
393
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy

NCT01314963
View directory record Official record
Conditions
Multiple Myeloma, Breast Cancer
Interventions
Prototype intraoperative handheld gamma camera (pIHGC), Lymphoscintigraphy with intraoperative gamma probes (GP), radioactive Tc99M
Device · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 27, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

NCT05042687
View directory record Official record
Conditions
Breast Cancer
Interventions
Tc99m sestamibi
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 27, 2026, 6:34 PM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 27, 2026, 6:34 PM EDT